Updated Safety and Efficacy from a Phase I Study of Azd9291 in Patients (Pts) with Egfr-Tki-Resistant Non-Small Cell Lung Cancer (Nsclc)

Yang, J.C-H.; Kim, D.; Planchard, David; Ohe, Yuichiro; Ramalingam, S.; Ahn, Myung‐Ju; Kim, S.; Su, Wu‐Chou; Horn, Leora; Haggstrom, Daniel; Felip, Enriqueta; Kim, J.; Frewer, Paul; Cantarini, Mireille; Ghiorghiu, Serban; Ranson, Malcolm R

doi:10.1093/annonc/mdu331.9

Cited by 19 publications

(18 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In phase I trials, AZD9291 and CO-1686 achieved response rates of 61% and 67%, respectively, in pretreated patients with acquired T790M mutations; response rates were 21% and 36%, respectively, in patients with T790M-negative tumors [28,29]. Median PFS with AZD9291 and CO-1686, respectively, was 9.6 months and 10.4 months in patients with T790M-positive tumors and 2.8 months and 7.5 months in patients with T790M-negative disease [28,29].…”

Section: Discussionmentioning

confidence: 99%

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors

Heigener

Schümann²,

Sebastian

et al. 2015

The Oncologist

View full text Add to dashboard Cite

Background. Afatinib, an irreversible ErbB family blocker, is approved for treatment of patients with previously untreated non-small cell lung cancer (NSCLC) harboring activating epidermal growth factor receptor (EGFR) mutations. Efficacy of afatinib in EGFR tyrosine kinase inhibitor-naïve (TKI-naïve) patients with uncommon EGFR mutations (other than exon 19 deletions or exon 21 point mutations) has been reported; however, efficacy in TKI-pretreated patients with uncommon EGFR mutations is unknown. Materials and Methods. In the afatinib compassionate use program (CUP), patients with advanced or metastatic, histologically confirmed NSCLC progressing after at least one line of chemotherapy and one line of EGFR-TKI treatment were enrolled. Demographic data, mutation type, response rates, time to treatment failure (TTF), and safety in patients harboring uncommon EGFR mutations were reported.

show abstract

Section: Discussionmentioning

confidence: 99%

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors

Heigener

Schümann²,

Sebastian

et al. 2015

The Oncologist

View full text Add to dashboard Cite

show abstract

“…This EGFR mutation test is registered in Europe for the detection of EGFR gene mutations [24] and has been granted premarket approval for use as the companion diagnostic test for TAGRISSO™ (osimertinib) in the USA [25]. This methodology was chosen for central laboratory EGFR mutation testing in the AURA clinical trial program including the Phase I study (NCT01802632) [17,26], which investigated the safety and efficacy of osimertinib in patients with advanced NSCLC and acquired resistance to EGFR-TKIs.…”

Section: Introductionmentioning

confidence: 99%

EGFR T790M mutation testing within the osimertinib AURA Phase I study

et al. 2017

View full text Add to dashboard Cite

“…This T790M germline mutation is associated with familial lung cancer. The clinical implication for a patient with a germline T790M mutation and a T790M mutation at diagnosis in the lung cancer is that while standard tyrosine kinase inhibitors are not apt to be effective, new tyrosine kinase inhibitors are under development which overcomes the T790M mutation such as AZD9291 [40]. The implication for family members who have this T790M germline mutation but who do not yet have lung cancer is still being worked out.…”

Section: Discussionmentioning

confidence: 99%

Germline mutations predisposing to non-small cell lung cancer

et al. 2015

View full text Add to dashboard Cite

Lung cancer in multiple first degree relatives had previously been attributed to smoking and to inherited enzymes associated with increased activation of carcinogens in smoke. There was not clear agreement on the significance of the testing methods for lung cancer susceptibility. More recent studies have identified germline mutations associated with lung cancer even in the absence of smoking and other mutations with plausible explanations for their association with lung cancer caused by smoking. At this time, the clinical significance of the various germline mutations for screening and the implications for therapy are not certain. This review summarizes the currently identified germline mutations associated with lung cancer, but this growing area of research will very likely identify further significant mutations as well.

show abstract

Updated Safety and Efficacy from a Phase I Study of Azd9291 in Patients (Pts) with Egfr-Tki-Resistant Non-Small Cell Lung Cancer (Nsclc)

Cited by 19 publications

References 0 publications

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors

Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors

EGFR T790M mutation testing within the osimertinib AURA Phase I study

Germline mutations predisposing to non-small cell lung cancer

Contact Info

Product

Resources

About